Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity

 Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity

Shots:

  • The company reported the results from the P-IIIa STEP 1 trial of the STEP programme assessing semaglutide (2.4 mg, SC, qw) vs PBO in adults with obesity for 68 wks. The results will be presented at ECO 2021
  • Results: The therapy showed 14.9% weight loss, 43.8% improvement in total weight-related QoL scores, 51.2% vs 32.9% participants improved weight-related physical function, 40% vs 27% participants achieved improvement in health-related physical functioning score, improved psychological well being
  • Semaglutide is an analogue of the human GLP-1 hormone, currently under investigation for chronic weight management and is under FDA and EMA’s review

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Novo Nordisk

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post